Disc Medicine (IRON) Non Operating Income (2021 - 2026)
Disc Medicine (IRON) reported Non Operating Income of $6.1 million for Q1 2026, up 1.52% year-over-year from $6.0 million in Q1 2025, and up 134.44% on a QoQ basis from -$17.6 million in Q4 2025.
Disc Medicine (IRON) has 6 years of Non Operating Income data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Non Operating Income rose 1.52% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136000.0 (down 98.71% YoY) and the FY2025 annual result came in at $45000.0, up 2350.0% from the prior year.
- Non Operating Income improved to $6.1 million in Q1 2026 per IRON's latest filing, from -$17.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $6.2 million in Q2 2025 and bottomed at -$17.6 million in Q4 2025.
- The 5-year median for Non Operating Income is $2.4 million (2022), against an average of $1.8 million.
- Peak annual rise in Non Operating Income reached 598100.0% in 2025, while the deepest fall reached 587666.67% in 2025.
- Tracing IRON's Non Operating Income over 5 years: stood at $648000.0 in 2022, then jumped by 851.7% to $6.2 million in 2023, then tumbled by 99.95% to $3000.0 in 2024, then sank by 587666.67% to -$17.6 million in 2025, then jumped by 134.44% to $6.1 million in 2026.
- Per Business Quant, the three latest IRON Non Operating Income figures stand at $6.1 million (Q1 2026), -$17.6 million (Q4 2025), and $5.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | 6.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.07 Mn |
| Dec 31, 2025 | -17.63 Mn |
| Sep 30, 2025 | 5.48 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Mar 31, 2025 | 5.98 Mn |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | 6.17 Mn |
| Sep 30, 2023 | 4.86 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Dec 31, 2022 | 648,000.00 |
| Jun 30, 2022 | 2.44 Mn |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | -5.02 Mn |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -11,000.00 |